Molecular Epidemiology of Hepatitis B Virus
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus kills at least 600,000 people annually worldwide and remains the leading global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Because the HBV reverse transcriptase lacks a proofreading function, many HBV genotypes,subgenotypes, mutants, and recombinants exist. At least 10 HBV genotypes (HBV-A through J) with distinct geographic distributions have been identified; by definition, their complete genomic sequences diverge by more than 8%. HBV genotype is increasingly becoming recognized as an important factor in the progression and clinical outcome of HBVinduced disease. Infections by HBV-C or -D are significantly more likely to lead to cirrhosis and hepatocellular carcinoma than are infections by HBV-A or -B. Additionally, the hepatitis B e antigen seroconversion response to standard or pegylated interferon is more favorable in patients with HBV-A or -B than in those with HBV-C or -D. However, therapeutic responses to nucleos(t)ide analogues are generally comparable among HBV genotypes. In conclusion, genotyping of HBV is useful in identifying chronic hepatitis B patients who are at increased risk of disease progression, thereby enabling physicians to optimize antiviral therapy for these patients.
Abstract
Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus kills at least 600,000 people annually worldwide and remains the leading global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Because the HBV reverse transcriptase lacks a proofreading function, many HBV genotypes,subgenotypes, mutants, and recombinants exist. At least 10 HBV genotypes (HBV-A through J) with distinct geographic distributions have been identified; by definition, their complete genomic sequences diverge by more than 8%. HBV genotype is increasingly becoming recognized as an important factor in the progression and clinical outcome of HBVinduced disease. Infections by HBV-C or -D are significantly more likely to lead to cirrhosis and hepatocellular carcinoma than are infections by HBV-A or -B. Additionally, the hepatitis B e antigen seroconversion response to standard or pegylated interferon is more favorable in patients with HBV-A or -B than in those with HBV-C or -D. However, therapeutic responses to nucleos(t)ide analogues are generally comparable among HBV genotypes. In conclusion, genotyping of HBV is useful in identifying chronic hepatitis B patients who are at increased risk of disease progression, thereby enabling physicians to optimize antiviral therapy for these patients.
참고문헌 (42)
- Kao JH, "Global control of hepatitis B virus infection", Lancet Infect Dis, 2, pp.395~403 (2002)
- Kao JH, "Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects", Adv Cancer Res, 108, pp.21~72 (2010)
- Fattovich G, "Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors", J Hepatol, 48, pp.335~352 (2008)
- Lau JY, "Molecular virology and pathogenesis of hepatitis B", Lancet, 342, pp.1335~1340 (1993)
- Kao JH, "Hepatitis B viral genotypes: clinical relevance and molecular characteristics", J Gastroenterol Hepatol, 17, pp.643~650 (2002)
- Kurbanov F, "Geographical and genetic diversity of the human hepatitis B virus", Hepatol Res, 40, pp.14~30 (2010)
- Lin CL, "Hepatitis B viral factors and clinical outcomes of chronic hepatitis B", J Biomed Sci, 15, pp.137~145 (2008)
- Lin CL, "The clinical implications of hepatitis B virus genotype: Recent advances", J Gastroenterol Hepatol, 26(1), pp.123~130 (2011)
- Kao JH, "HBV genotypes: epidemiology and implications regarding natural history", Curr Hepat Rep, 5, pp.5~13 (2006)
- Datta S, "An overview of molecular epidemiology of hepatitis B virus (HBV) in India", Virol J, 5, pp.156~ (2008)
- Phung TB, "Genotype X", C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam: genotypes B4 and C1 predominate, 2010, pp.82, 1327~1333
- Tatematsu K, "A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J", J Virol, 83, pp.10528~10547 (2009)
- McMahon BJ, "The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B", Hepatol Int, 3, pp.334~342 (2009)
- Yang HI, "Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.1134~1143 (2008)
- Chen JD, "Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma", Clin Gastroenterol Hepatol, 2, pp.64~71 (2004)
- Lin CL, "Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma", J Viral Hepat, 14, pp.64~69 (2007)
- Sanchez-Tapias JM, "Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients", Gastroenterology, 123, pp.1848~1856 (2002)
- Livingston SE, "Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F", J Infect Dis, 195, pp.5~11 (2007)
- Yang HI, "Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection", J Clin Oncol, 28, pp.2437~2444 (2010)
- Sugiyama M, "Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens", Hepatology, 44, pp.915~924 (2006)
- Liu CJ, "Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B", J Infect Dis, 199, pp.742~749 (2009)
- Chen RY, "Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus", J Gastroenterol Hepatol, 18, pp.630~637 (2003)
- Liu CJ, "Therapeutic implications of hepatitis B virus genotypes", Liver Int, 25, pp.1097~1107 (2005)
- Liu CJ, "Genetic variability of hepatitis B virus and response to antiviral therapy", Antivir Ther, 13, pp.613~624 (2008)
- Kao JH, "Hepatitis B genotypes and the response to interferon therapy", J Hepatol, 33, pp.998~1002 (2000)
- Erhardt A, "Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D", Gut, 54, pp.1009~1013 (2005)
- Cooksley WG, "Peginterferon alpha- 2a (40 kDa): an advance in the treatment of hepatitis B e antigen- positive chronic hepatitis B", J Viral Hepat, 10, pp.298~305 (2003)
- Lau GK, "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
- Zhao H, "Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated", nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China, 2007, pp.44, 541~548
- Janssen HL, "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial", Lancet, 365, pp.123~129 (2005)
- Flink HJ, "Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype", Am J Gastroenterol, 101, pp.297~303 (2006)
- Buster EH, "Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b", Gastroenterology, 135, pp.459~467 (2008)
- Marcellin P, "Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a", Gastroenterology, 136, pp.2169~2179 (2009)
- Moucari R, "Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a", Antivir Ther, 14, pp.1183~1188 (2009)
- Wiegand J, "Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence", Antivir Ther, 13, pp.211~220 (2008)
- Raimondi S, "Is response to antiviral treatment influenced by hepatitis B virus genotype", J Hepatol, 52, pp.441~449 (2010)
- Buster EH, "Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa", Gastroenterology, 137, pp.2002~2009 (2009)
- Hsieh TH, "Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C", Antivir Ther, 14, pp.1157~1163 (2009)
- Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
- Kao JH, "Role of viral factors in the natural course and therapy of chronic hepatitis B", Hepatol Int, 1, pp.415~430 (2007)
- Kao JH, "Appropriate use of interferon for treatment of chronic hepatitis B", Hepatol Res, 37(1), pp.47~54 (2007)
- Cooksley WG, "Do we need to determine viral genotype in treating chronic hepatitis B", J Viral Hepat, 17, pp.601~610 (2010)